T1	Participants 581 587	2 arms
T2	Participants 345 513	a double-blind, placebo-controlled, randomized trial of EFV plus indinavir (EFV+IDV) vs. EFV+IDV plus abacavir (ABC) in 283 nucleoside-experienced HIV-infected patients
T3	Participants 994 1002	patients
T4	Participants 1413 1420	patient
